Marburg
Germany
78
2024-01-04
63
2023-01-17
These are the the leading inventors for applications assigned to CSL BEHRING GMBH:
CSL BEHRING GMBH based in Marburg, DE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Method for Treating Antibody-Mediated Rejection
#2 | 2022-11-17Process for Purifying C1-INH
#3 | 2021-12-09PROCESS FOR PURIFYING C1-INH
#4 | 2020-12-17 ✅ Patent 11,554,156 granted on 2023-01-17Pharmaceutical formulations of C1 esterase inhibitor
#5 | 2020-06-25METHOD FOR VIRUS FILTRATION OF VON WILLEBRAND FACTOR
#6 | 2020-04-30 ✅ Patent 12,065,481 granted on 2024-08-20Therapy using a factor XII inhibitor in a neurotraumatic disorder
#7 | 2020-02-27 ✅ Patent 11,345,759 granted on 2022-05-31Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
#8 | 2019-11-21 ✅ Patent 11,744,880 granted on 2023-09-05Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
#9 | 2019-09-05 ✅ Patent 10,973,891 granted on 2021-04-13Treatment and prevention of remote ischemia-reperfusion injury
#10 | 2019-07-11 ✅ Patent 11,426,680 granted on 2022-08-30Hydrophobic charge induction chromatographic protein depleted solution
#11 | 2018-05-17 ✅ Patent 10,513,560 granted on 2019-12-24Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
#12 | 2018-05-03PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY
#13 | 2018-02-08PHARMACEUTICAL FORMULATIONS OF C1 ESTERASE INHIBITOR
#14 | 2017-09-28 ✅ Patent 10,232,015 granted on 2019-03-19Sugar compositions for treating hemophilia A and/or Von Willebrand disease
#15 | 2017-07-27IMPROVED FACTOR VIII PREPARATIONS SUITABLE FOR THERAPEUTIC USE AND PROCESSES TO OBTAIN THESE
#16 | 2017-05-25METHOD OF PURIFYING THERAPEUTIC PROTEINS
#17 | 2017-05-18 ✅ Patent 9,856,326 granted on 2018-01-02Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
#18 | 2017-05-04 ✅ Patent 9,856,325 granted on 2018-01-02Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies
#19 | 2017-04-27THERAPY USING A FACTOR XII INHIBITOR IN A NEUROTRAUMATIC DISORDER
#20 | 2016-09-29 ✅ Patent 9,987,328 granted on 2018-06-05Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
#21 | 2016-01-14 ✅ Patent 10,286,047 granted on 2019-05-14Treatment and prevention of remote ischemia-reperfusion injury
#22 | 2016-01-14 ✅ Patent 10,441,631 granted on 2019-10-15Therapeutic agent for amniotic fluid embolism
#23 | 2015-12-24 ✅ Patent 10,188,965 granted on 2019-01-29Hydrophobic charge induction chromatographic depletion of a protein from a solution
#24 | 2015-06-11 ✅ Patent 9,598,461 granted on 2017-03-21Method of purifying therapeutic proteins
#25 | 2015-06-04METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS
#26 | 2015-03-26 ✅ Patent 9,707,269 granted on 2017-07-18Sugar compositions for treating hemophilia A and/or von Willebrand disease
#27 | 2015-01-22 ✅ Patent 9,511,123 granted on 2016-12-06Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
#28 | 2014-12-25 ✅ Patent 9,957,329 granted on 2018-05-01Factor XII inhibitors for the treatment of neurological inflammatory disorders
#29 | 2014-12-18 ✅ Patent 9,452,203 granted on 2016-09-27Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
#30 | 2014-12-04 ✅ Patent 9,458,223 granted on 2016-10-04Von willebrand factor variants having improved factor VIII binding affinity
#31 | 2014-12-04MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE
#32 | 2014-10-23 ✅ Patent 9,393,289 granted on 2016-07-19Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII
#33 | 2014-09-18MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE
#34 | 2014-09-04THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY
#35 | 2014-08-21 ✅ Patent 10,471,142 granted on 2019-11-12Combination therapy using immunoglobulin and C1-Inhibitor
#36 | 2014-07-17 ✅ Patent 9,518,127 granted on 2016-12-13Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses
#37 | 2014-05-08 ✅ Patent 9,095,564 granted on 2015-08-04von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
#38 | 2014-04-03 ✅ Patent 8,962,802 granted on 2015-02-24Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1
#39 | 2014-03-13 ✅ Patent 9,352,016 granted on 2016-05-31Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
#40 | 2014-03-13 ✅ Patent 9,624,307 granted on 2017-04-18Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
#41 | 2014-03-13 ✅ Patent 9,290,561 granted on 2016-03-22Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
#42 | 2013-12-19THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY
#43 | 2013-10-31 ✅ Patent 8,653,245 granted on 2014-02-18Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1
#44 | 2013-07-11ANCESTRAL SERINE PROTEASE COAGULATION CASCADE EXERTS A NOVEL FUNCTION IN EARLY IMMUNE DEFENSE
#45 | 2013-06-27 ✅ Patent 8,715,672 granted on 2014-05-06Treatment of diseases linked to pathological kinin formation
#46 | 2013-05-09 ✅ Patent 9,474,851 granted on 2016-10-25Holder for an injection syringe
#47 | 2013-01-03 ✅ Patent 8,580,737 granted on 2013-11-12Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
#48 | 2012-09-20 ✅ Patent 8,877,711 granted on 2014-11-04Octanoate-reduced human albumin
#49 | 2011-07-28 ✅ Patent 8,575,104 granted on 2013-11-05Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
#50 | 2011-06-09 ✅ Patent 8,618,464 granted on 2013-12-31Device and method for detecting broken glass in a conveyor sterilization tunnel
#51 | 2011-05-12 ✅ Patent 8,603,979 granted on 2013-12-10von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
#52 | 2011-04-14 ✅ Patent 8,436,152 granted on 2013-05-07Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1
#53 | 2011-02-24 ✅ Patent 10,137,165 granted on 2018-11-27Factor H for the treatment of chronic nephropathies and production thereof
#54 | 2010-11-11 ✅ Patent 9,107,902 granted on 2015-08-18Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
#55 | 2010-11-09 ✅ Patent 7,829,095 granted on 2010-11-09Inhibitory monoclonal antibody against blood clotting factor VII-activating protease
#56 | 2010-11-04 ✅ Patent 8,283,319 granted on 2012-10-09Therapeutic application of Kazal-type serine protease inhibitors
#57 | 2010-05-13 ✅ Patent 8,754,194 granted on 2014-06-17Modified coagulation factors with prolonged in vivo half-life
#58 | 2010-04-15 ✅ Patent 8,394,768 granted on 2013-03-12Synergistic therapeutic use of Prothrombin Complex Concentrates with FVIII concentrates
#59 | 2009-12-31 ✅ Patent 8,051,884 granted on 2011-11-08Device for combining components by means of negative pressure under sterile conditions
#60 | 2009-12-03 ✅ Patent 8,765,915 granted on 2014-07-01Modified coagulation factor VIIa with extended half-life
#61 | 2009-12-01 ✅ Patent 7,625,866 granted on 2009-12-01Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating thereto
#62 | 2009-07-09 ✅ Patent 9,347,051 granted on 2016-05-24Coagulation factor X polypeptides with modified activation properties
#63 | 2009-06-25 ✅ Patent 7,863,009 granted on 2011-01-04Mutants of the factor VII-activating protease and detection methods using specific antibodies
#64 | 2009-05-21 ✅ Patent 8,828,939 granted on 2014-09-09Modified vitamin K dependent polypeptides
#65 | 2009-04-02 ✅ Patent 7,892,842 granted on 2011-02-22Procedure for the determination of the activity of the protease which activates factor VII from protein solutions
#66 | 2009-02-26 ✅ Patent 9,249,404 granted on 2016-02-02Coagulation factor X polypeptides with modified activation properties
#67 | 2009-02-17 ✅ Patent 7,491,197 granted on 2009-02-17Fluid transfer device
#68 | 2008-10-23 ✅ Patent 7,939,288 granted on 2011-05-10Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques
#69 | 2008-10-23 ✅ Patent 7,939,632 granted on 2011-05-10Proteolytically cleavable fusion proteins with high molar specific activity
#70 | 2008-07-24 ✅ Patent 7,879,803 granted on 2011-02-01Methods of treatment involving the protease for activating clotting factor VII
#71 | 2008-04-01 ✅ Patent 7,351,561 granted on 2008-04-01Thrombin preparations and process for their production
#72 | 2008-01-03 ✅ Patent 7,572,769 granted on 2009-08-11Fibrin adhesive granulate and method for its preparation
#73 | 2007-10-04 ✅ Patent 7,863,006 granted on 2011-01-04Antibodies for specifically detecting pathogenic prions of human origin, and detection methods carried out using these antibodies
#74 | 2007-05-03 ✅ Patent 7,803,569 granted on 2010-09-28Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
#75 | 2006-08-17 ✅ Patent 8,012,728 granted on 2011-09-06Thrombin preparations and process for their production
#76 | 2005-12-22 ✅ Patent 7,335,634 granted on 2008-02-26Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers
#77 | 2005-09-08 ✅ Patent 7,550,567 granted on 2009-06-23Fibrinogen purification
#78 | 2005-02-10 ✅ Patent 7,442,514 granted on 2008-10-28Mutants of the factor VII-activating protease and detection methods using specific antibodies
Also check out CSL Behring GmbH's (Marburg, Germany) applicant profile with 24 patent applications submitted.
21951 ⎘